This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#148

PACAP (Pituitary Adenylate Cyclase-Activating Peptide)

NeuroprotectivePACAP-38PACAP-27ADCYAP1

A highly conserved neuropeptide with potent neuroprotective, neurotrophic, and anti-inflammatory properties, investigated for neurological disorders and increasingly recognized in migraine pathophysiology.

Overview

PACAP (Pituitary Adenylate Cyclase-Activating Peptide) is a neuropeptide discovered in 1989 by Akira Arimura's laboratory from ovine hypothalamic extracts based on its ability to stimulate adenylate cyclase in pituitary cells. It exists in two bioactive forms: PACAP-38 (38 amino acids, the predominant form) and PACAP-27 (27 amino acids). PACAP belongs to the VIP/secretin/glucagon superfamily and shares 68% sequence homology with vasoactive intestinal peptide (VIP), reflecting a common evolutionary origin.

PACAP is one of the most evolutionarily conserved peptides known — its sequence is virtually identical across vertebrate species from fish to humans, suggesting critical biological functions. PACAP acts through three receptors: PAC1 (specific for PACAP), VPAC1, and VPAC2 (shared with VIP). Through PAC1 receptors, PACAP activates multiple intracellular signaling cascades including cAMP/PKA, PLC/PKC, and MAPK pathways, providing a diverse range of downstream effects.

The neuroprotective properties of PACAP have been extensively documented. In animal models, PACAP protects neurons against excitotoxicity, oxidative stress, ischemia, and traumatic brain injury. It promotes neuronal survival, neurite outgrowth, and axonal regeneration. The peptide reduces neuroinflammation by modulating microglial activation and shifting inflammatory responses toward resolution. These properties have generated interest in PACAP-based therapies for stroke, traumatic brain injury, neurodegenerative diseases, and peripheral nerve injury.

PACAP has also emerged as an important molecule in migraine pathophysiology. Intravenous PACAP-38 infusion reliably triggers migraine attacks in susceptible individuals, similar to CGRP. Plasma PACAP levels are elevated during migraine attacks. This discovery has led to the investigation of PAC1 receptor antibodies and antagonists for migraine prevention, positioning PACAP as a potential next-generation target following the success of CGRP-targeted migraine therapies.

Research Uses & Applications

Investigated for neuroprotective therapy in stroke and traumatic brain injury
Target pathway for migraine prevention drug development (PAC1 receptor antibodies)
Studied for neurodegenerative disease treatment including Alzheimer's and Parkinson's
Research into peripheral nerve regeneration and repair
Investigated for retinal neuroprotection in glaucoma and retinal degeneration
Studied for anti-inflammatory effects in neuroinflammatory conditions

Key Research Findings

IV PACAP-38 infusion triggered migraine attacks in 58% of migraine patients versus 15% with placebo, establishing PACAP as a migraine mediator (Schytz et al., Brain, 2009).
Preclinical stroke studies showed PACAP administration reduced infarct volume by 40-60% when given within hours of ischemic injury in rodent models.
Research demonstrated PACAP promotes motor neuron survival and axonal regeneration after peripheral nerve injury in multiple animal models.
Studies showed PACAP-deficient mice develop accelerated neurodegeneration and increased vulnerability to brain injury.
Phase 2 clinical trials of anti-PAC1 receptor antibodies for migraine prevention are in progress, representing the next frontier after CGRP-targeting therapies.

Risks & Side Effects

PACAP is not currently used as a therapeutic agent due to rapid degradation and broad biological effects.
IV PACAP causes flushing, hypotension, tachycardia, and can trigger migraine attacks.
Broad receptor expression means systemic PACAP administration affects cardiovascular, gastrointestinal, and immune systems.
Short half-life (5-10 minutes) requires continuous infusion or structural modification for sustained effects.
PAC1 receptor antibodies for migraine may affect neuroprotective functions of PACAP signaling.

Administration

In clinical research, PACAP-38 is administered IV at 10-20 pmol/kg/min for migraine provocation studies. Animal neuroprotection studies use intracerebroventricular, intrathecal, or IV administration at doses of 0.01-1 mcg. PAC1 receptor antibodies are administered as subcutaneous injections in clinical trials (monthly dosing typical for migraine prevention). Available as a research peptide.

Legal Status

Available as a research chemical from scientific suppliers. Not approved for therapeutic use. PAC1 receptor-targeting antibodies are investigational drugs in clinical trials. Not a controlled substance.

Frequently Asked Questions

What is PACAP (Pituitary Adenylate Cyclase-Activating Peptide)?

What are the main uses of PACAP (Pituitary Adenylate Cyclase-Activating Peptide)?

The primary research applications of PACAP (Pituitary Adenylate Cyclase-Activating Peptide) include: Investigated for neuroprotective therapy in stroke and traumatic brain injury; Target pathway for migraine prevention drug development (PAC1 receptor antibodies); Studied for neurodegenerative disease treatment including Alzheimer's and Parkinson's; Research into peripheral nerve regeneration and repair; Investigated for retinal neuroprotection in glaucoma and retinal degeneration; Studied for anti-inflammatory effects in neuroinflammatory conditions.

What are the risks and side effects of PACAP (Pituitary Adenylate Cyclase-Activating Peptide)?

Documented risks and side effects include: PACAP is not currently used as a therapeutic agent due to rapid degradation and broad biological effects.; IV PACAP causes flushing, hypotension, tachycardia, and can trigger migraine attacks.; Broad receptor expression means systemic PACAP administration affects cardiovascular, gastrointestinal, and immune systems.; Short half-life (5-10 minutes) requires continuous infusion or structural modification for sustained effects.; PAC1 receptor antibodies for migraine may affect neuroprotective functions of PACAP signaling.. Always consult a healthcare professional before considering any peptide.

Is PACAP (Pituitary Adenylate Cyclase-Activating Peptide) legal?

How is PACAP (Pituitary Adenylate Cyclase-Activating Peptide) administered?

Related Peptides

#17

Selank

Neuroprotective

#18

Semax

Neuroprotective

#36

Cerebrolysin

Neuroprotective

#147

Orexin-B (Hypocretin-2)

Sleep & Recovery

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #147 Orexin-B (Hypocretin-2)#149 CGRP (Calcitonin Gene-Related Peptide) →